Normal-release oral morphine starting dose in cancer patients with pain

Clinical Journal of Pain

Volumn 25, Issue 5, 2009, Pages 386-390

  Ripamonti, Carla I ^a   Campa, Tiziana ^a   Fagnoni, Elena ^a   Brunelli, Cinzia ^a   Luzzani, Massimo ^b   Maltoni, Marco ^c   De Conno, Franco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Ospedale Civile di Forlimpopoli Dip   (Italy)

Author keywords

Cancer pain; Normal release morphine; Opioids; Pain intensity; Routine practice

Indexed keywords

MORPHINE SULFATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ANALGESIA; ARTICLE; BEDTIME DOSAGE; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG RELEASE; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPATHIC PAIN; PAIN ASSESSMENT; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RECOMMENDED DRUG DOSE;

EID: 67649550733     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e3181929b4f     Document Type: Article

References (15)

1. World Health Organization. Model List of Essential Drugs (EDL), 11th ed. November 1999. Available at: www.who.int/ medicines/organization/par/edl/infed 111 group.litml
2. World Health Organization. Cancer Pain Relief. Geneva: World Health Organization; 1986.
3. World Health Organization. Cancer Pain Relief. 2nd ed. Geneva: World Health Organization; 1996.
4. World Health Organization. Pain ladder for cancer pain relief. Available at: http://www.who.int/cancer/palliative/painladder/ en/ Assessed on March 12, 2008.
5. Hanks GW, De Conno F, Cherny N, et al, and the Expert Working Group of the Research Network of the EAPC. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001;84:587-593.
6. Hanks GW, De Conno F, Ripamonti C, et al, Expert Working Group of the European Association of Palliative Care. Morphine in cancer pain: modes of administration. BMJ. 1996;312:823-826.
7. Joint Formulary Committee. British National Formulary. 53rd ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2007.
8. Guide to the use of Medicines based on British National Formulary, Cap 1, Par 1.3.1 Dolore; 2005 N 3. Available at: www.guidausofarmaci.it
9. De Conno F, Ripamonti C, Fagnoni E, et al. The MERITO Study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during "titration phase" in patients with cancer pain. Palliat Med. 2008;22:214-221.
10. Mercadante S, Dardanoni G, Salvaggio L, et al. Monitoring of opioid therapy in advanced cancer pain patients. J Pain Symptom Manage. 1997;13:204-212.
11. International Association for the Study of Pain. Subcommittee on Taxonomy. Classification of chronic pain. Descriptors of chronic pain syndromes and definition of pain terms. Pain. 1986;3:S1-S226.
12. Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain. Consensus conference of an Expert Working Group of the European Association for Palliative Care. Cancer. 2002;94:832-839.
13. Ripamonti C, Fagnoni E, Campa T, et al. Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Support Care Cancer. 2006;14:400-407.
14. Chinellato A, Terrazzani G, Walley T, et al. Opioids in Italy: is marketing more powerful than the law? Lancet. 2003;362:78.
15. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain. 1990;43:273-286.